Opportunities to investigate the effects of ivermectin mass drug administration on scabies
Identifieur interne : 002480 ( Pmc/Corpus ); précédent : 002479; suivant : 002481Opportunities to investigate the effects of ivermectin mass drug administration on scabies
Auteurs : Daniel Engelman ; Diana L. Martin ; Roderick J. Hay ; Olivier Chosidow ; James S. Mccarthy ; L Claire Fuller ; Andrew C. SteerSource :
- Parasites & Vectors [ 1756-3305 ] ; 2013.
Abstract
The recent article by Mohammed
Url:
DOI: 10.1186/1756-3305-6-106
PubMed: 23594459
PubMed Central: 3639091
Links to Exploration step
PMC:3639091Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Opportunities to investigate the effects of ivermectin mass drug administration on scabies</title><author><name sortKey="Engelman, Daniel" sort="Engelman, Daniel" uniqKey="Engelman D" first="Daniel" last="Engelman">Daniel Engelman</name><affiliation><nlm:aff id="I1">Centre for International Child Health, University of Melbourne, Royal Children’s Hospital Melbourne, Flemington Road, Parkville, Melbourne 3052, Australia</nlm:aff></affiliation></author><author><name sortKey="Martin, Diana L" sort="Martin, Diana L" uniqKey="Martin D" first="Diana L" last="Martin">Diana L. Martin</name><affiliation><nlm:aff id="I2">Centers for Disease Control and Prevention, Atlanta, USA</nlm:aff></affiliation></author><author><name sortKey="Hay, Roderick J" sort="Hay, Roderick J" uniqKey="Hay R" first="Roderick J" last="Hay">Roderick J. Hay</name><affiliation><nlm:aff id="I3">International Foundation for Dermatology, London, UK</nlm:aff></affiliation></author><author><name sortKey="Chosidow, Olivier" sort="Chosidow, Olivier" uniqKey="Chosidow O" first="Olivier" last="Chosidow">Olivier Chosidow</name><affiliation><nlm:aff id="I4">Department of Dermatology, AP-HP, Hôpital Henri Mondor, Université Paris-est Créteil Val de Marne, Créteil, France</nlm:aff></affiliation></author><author><name sortKey="Mccarthy, James S" sort="Mccarthy, James S" uniqKey="Mccarthy J" first="James S" last="Mccarthy">James S. Mccarthy</name><affiliation><nlm:aff id="I5">Queensland Institute of Medical Research, Brisbane, Australia</nlm:aff></affiliation></author><author><name sortKey="Fuller, L Claire" sort="Fuller, L Claire" uniqKey="Fuller L" first="L Claire" last="Fuller">L Claire Fuller</name><affiliation><nlm:aff id="I6">Chelsea and Westminster Hospital, London, UK</nlm:aff></affiliation></author><author><name sortKey="Steer, Andrew C" sort="Steer, Andrew C" uniqKey="Steer A" first="Andrew C" last="Steer">Andrew C. Steer</name><affiliation><nlm:aff id="I1">Centre for International Child Health, University of Melbourne, Royal Children’s Hospital Melbourne, Flemington Road, Parkville, Melbourne 3052, Australia</nlm:aff></affiliation><affiliation><nlm:aff id="I7">Murdoch Childrens Research Institute, Melbourne, Australia</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">23594459</idno><idno type="pmc">3639091</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639091</idno><idno type="RBID">PMC:3639091</idno><idno type="doi">10.1186/1756-3305-6-106</idno><date when="2013">2013</date><idno type="wicri:Area/Pmc/Corpus">002480</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002480</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Opportunities to investigate the effects of ivermectin mass drug administration on scabies</title><author><name sortKey="Engelman, Daniel" sort="Engelman, Daniel" uniqKey="Engelman D" first="Daniel" last="Engelman">Daniel Engelman</name><affiliation><nlm:aff id="I1">Centre for International Child Health, University of Melbourne, Royal Children’s Hospital Melbourne, Flemington Road, Parkville, Melbourne 3052, Australia</nlm:aff></affiliation></author><author><name sortKey="Martin, Diana L" sort="Martin, Diana L" uniqKey="Martin D" first="Diana L" last="Martin">Diana L. Martin</name><affiliation><nlm:aff id="I2">Centers for Disease Control and Prevention, Atlanta, USA</nlm:aff></affiliation></author><author><name sortKey="Hay, Roderick J" sort="Hay, Roderick J" uniqKey="Hay R" first="Roderick J" last="Hay">Roderick J. Hay</name><affiliation><nlm:aff id="I3">International Foundation for Dermatology, London, UK</nlm:aff></affiliation></author><author><name sortKey="Chosidow, Olivier" sort="Chosidow, Olivier" uniqKey="Chosidow O" first="Olivier" last="Chosidow">Olivier Chosidow</name><affiliation><nlm:aff id="I4">Department of Dermatology, AP-HP, Hôpital Henri Mondor, Université Paris-est Créteil Val de Marne, Créteil, France</nlm:aff></affiliation></author><author><name sortKey="Mccarthy, James S" sort="Mccarthy, James S" uniqKey="Mccarthy J" first="James S" last="Mccarthy">James S. Mccarthy</name><affiliation><nlm:aff id="I5">Queensland Institute of Medical Research, Brisbane, Australia</nlm:aff></affiliation></author><author><name sortKey="Fuller, L Claire" sort="Fuller, L Claire" uniqKey="Fuller L" first="L Claire" last="Fuller">L Claire Fuller</name><affiliation><nlm:aff id="I6">Chelsea and Westminster Hospital, London, UK</nlm:aff></affiliation></author><author><name sortKey="Steer, Andrew C" sort="Steer, Andrew C" uniqKey="Steer A" first="Andrew C" last="Steer">Andrew C. Steer</name><affiliation><nlm:aff id="I1">Centre for International Child Health, University of Melbourne, Royal Children’s Hospital Melbourne, Flemington Road, Parkville, Melbourne 3052, Australia</nlm:aff></affiliation><affiliation><nlm:aff id="I7">Murdoch Childrens Research Institute, Melbourne, Australia</nlm:aff></affiliation></author></analytic><series><title level="j">Parasites & Vectors</title><idno type="eISSN">1756-3305</idno><imprint><date when="2013">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>The recent article by Mohammed <italic>et al.</italic> demonstrates an impressive effect of ivermectin mass drug administration for lymphatic filariasis on the burden of scabies. Partnering scabies research within the evaluation and monitoring of Neglected Tropical Disease programmes could potentially increase our understanding of the epidemiology and control of scabies and its important bacterial complications.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Mohammed, Ka" uniqKey="Mohammed K">KA Mohammed</name></author><author><name sortKey="Deb, Rm" uniqKey="Deb R">RM Deb</name></author><author><name sortKey="Stanton, Mc" uniqKey="Stanton M">MC Stanton</name></author><author><name sortKey="Molyneux, Dh" uniqKey="Molyneux D">DH Molyneux</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hay, Rj" uniqKey="Hay R">RJ Hay</name></author><author><name sortKey="Steer, Ac" uniqKey="Steer A">AC Steer</name></author><author><name sortKey="Chosidow, O" uniqKey="Chosidow O">O Chosidow</name></author><author><name sortKey="Currie, Bj" uniqKey="Currie B">BJ Currie</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lawrence, G" uniqKey="Lawrence G">G Lawrence</name></author><author><name sortKey="Leafasia, J" uniqKey="Leafasia J">J Leafasia</name></author><author><name sortKey="Sheridan, J" uniqKey="Sheridan J">J Sheridan</name></author><author><name sortKey="Hills, S" uniqKey="Hills S">S Hills</name></author><author><name sortKey="Wate, J" uniqKey="Wate J">J Wate</name></author><author><name sortKey="Wate, C" uniqKey="Wate C">C Wate</name></author><author><name sortKey="Montgomery, J" uniqKey="Montgomery J">J Montgomery</name></author><author><name sortKey="Pandeya, N" uniqKey="Pandeya N">N Pandeya</name></author><author><name sortKey="Purdie, D" uniqKey="Purdie D">D Purdie</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct></listBibl></div1></back></TEI><pmc article-type="letter" xml:lang="en"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Parasit Vectors</journal-id><journal-id journal-id-type="iso-abbrev">Parasit Vectors</journal-id><journal-title-group><journal-title>Parasites & Vectors</journal-title></journal-title-group><issn pub-type="epub">1756-3305</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23594459</article-id><article-id pub-id-type="pmc">3639091</article-id><article-id pub-id-type="publisher-id">1756-3305-6-106</article-id><article-id pub-id-type="doi">10.1186/1756-3305-6-106</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter to the Editor</subject></subj-group></article-categories><title-group><article-title>Opportunities to investigate the effects of ivermectin mass drug administration on scabies</article-title></title-group><contrib-group><contrib contrib-type="author" id="A1"><name><surname>Engelman</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>daniel.engelman@rch.org.au</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Martin</surname><given-names>Diana L</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>hzx3@cdc.gov</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Hay</surname><given-names>Roderick J</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>roderick.hay@ifd.org</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Chosidow</surname><given-names>Olivier</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>olivier.chosidow@hmn.aphp.fr</email></contrib><contrib contrib-type="author" id="A5"><name><surname>McCarthy</surname><given-names>James S</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>j.mccarthy@uq.edu.au</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Fuller</surname><given-names>L Claire</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>claire.fuller@nhs.net</email></contrib><contrib contrib-type="author" corresp="yes" id="A7"><name><surname>Steer</surname><given-names>Andrew C</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I7">7</xref><email>Andrew.Steer@rch.org.au</email></contrib></contrib-group><aff id="I1"><label>1</label>Centre for International Child Health, University of Melbourne, Royal Children’s Hospital Melbourne, Flemington Road, Parkville, Melbourne 3052, Australia</aff><aff id="I2"><label>2</label>Centers for Disease Control and Prevention, Atlanta, USA</aff><aff id="I3"><label>3</label>International Foundation for Dermatology, London, UK</aff><aff id="I4"><label>4</label>Department of Dermatology, AP-HP, Hôpital Henri Mondor, Université Paris-est Créteil Val de Marne, Créteil, France</aff><aff id="I5"><label>5</label>Queensland Institute of Medical Research, Brisbane, Australia</aff><aff id="I6"><label>6</label>Chelsea and Westminster Hospital, London, UK</aff><aff id="I7"><label>7</label>Murdoch Childrens Research Institute, Melbourne, Australia</aff><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>17</day><month>4</month><year>2013</year></pub-date><volume>6</volume><fpage>106</fpage><lpage>106</lpage><history><date date-type="received"><day>11</day><month>4</month><year>2013</year></date><date date-type="accepted"><day>15</day><month>4</month><year>2013</year></date></history><permissions><copyright-statement>Copyright © 2013 Engelman et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Engelman et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.parasitesandvectors.com/content/6/1/106"></self-uri><abstract><p>The recent article by Mohammed <italic>et al.</italic> demonstrates an impressive effect of ivermectin mass drug administration for lymphatic filariasis on the burden of scabies. Partnering scabies research within the evaluation and monitoring of Neglected Tropical Disease programmes could potentially increase our understanding of the epidemiology and control of scabies and its important bacterial complications.</p></abstract><kwd-group><kwd>Scabies</kwd><kwd>Ivermectin</kwd><kwd>Mass drug administration</kwd><kwd>Neglected tropical disease</kwd></kwd-group></article-meta></front><body><sec><title></title><p>We read with interest the article by Mohammed <italic>et al.</italic> in the December 21st issue of <italic>Parasites & Vectors</italic>[<xref ref-type="bibr" rid="B1">1</xref>]<italic>.</italic></p><p>The authors assessed the impact of an annual ivermectin mass drug administration (MDA) programme for lymphatic filariasis (LF) in Zanzibar, Tanzania, on the burden of scabies, using what they term a “rapid assessment” methodology. This involved retrospective review of health clinic records for the number of patients diagnosed and treated for scabies. The study observed a reduction of 68-98% in scabies cases over a five year period, indicating that annual MDA with ivermectin appears to have a significant effect on the burden of scabies in the community. Importantly, the reduction was also observed in children aged less than 5 years, who were not included in the ivermectin programme.</p><p>Whilst the study did not aim to show causation, the data represent some of the best available evidence demonstrating the effects of MDA programmes on other neglected tropical diseases (NTDs), and are the first indication of the potential impact on scabies. Understanding these additional effects is extremely important for the optimal design of integrated NTD control strategies, yet they have been overlooked in programmes to date.</p><p>Scabies is frequently complicated by bacterial skin infection (impetigo) which, in turn, can lead to a number of disease processes that carry significant morbidity, including severe soft tissue infections, invasive streptococcal and staphylococcal disease, acute post-streptococcal glomerulonephritis and possibly rheumatic heart disease [<xref ref-type="bibr" rid="B2">2</xref>]. Global efforts toward the control of scabies are particularly important to reduce the underappreciated morbidity and mortality of these secondary bacterial complications. Initial data suggest that MDA with ivermectin can not only reduce scabies prevalence, but reduce the burden of bacterial skin infection and indirect markers of renal damage (haematuria) [<xref ref-type="bibr" rid="B3">3</xref>].</p><p>There is a very large potential for increasing our understanding of the epidemiology and control of scabies through a research partnership, linking scabies with existing NTD control programmes. A number of simple measures introduced, as part of NTD monitoring and MDA evaluation, could provide invaluable information on the impact of ivermectin MDA on scabies and bacterial complications.</p><p>Whilst we applaud the authors for the publication of the rapid assessment method as an alternative to tests for parasite detection, a more direct evaluation of scabies prevalence would provide a better understanding of the effect of ivermectin MDA on disease burden. This could involve an annual cross-sectional prevalence study for scabies and impetigo in sentinel areas receiving ivermectin MDA. The International Alliance for the Control of Scabies (IACS) is working toward development and validation of protocols and case definitions for the diagnosis of scabies and impetigo, which are needed for both clinical and public health settings. Larger population samples would be required to examine the effect of ivermectin MDA on scabies complications such as invasive bacterial infection, renal and cardiac disease, but these are all feasible given the scope of current MDA programmes; for example the LF programme treated more than 500 million people in 2011 [<xref ref-type="bibr" rid="B4">4</xref>].</p><p>As now well established in the London Declaration [<xref ref-type="bibr" rid="B5">5</xref>], through creative collaborations outside of traditional disease-focussed programmes, comprehensive prevention and control strategies can yield increased benefits across a range of health outcomes for the most disadvantaged global populations.</p></sec><sec><title>Abbreviations</title><p>LF: Lymphatic filariasis; NTD: Neglected tropical disease; MDA: Mass drug administration.</p></sec><sec><title>Competing interests</title><p>The authors declare they have no competing interests.</p></sec><sec><title>Authors’ contributions</title><p>All authors helped to draft the manuscript, and have read and approved the final manuscript.</p></sec><sec><title>Authors’ information</title><p>All authors are members of the International Alliance for the Control of Scabies (IACS).</p></sec></body><back><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Mohammed</surname><given-names>KA</given-names></name><name><surname>Deb</surname><given-names>RM</given-names></name><name><surname>Stanton</surname><given-names>MC</given-names></name><name><surname>Molyneux</surname><given-names>DH</given-names></name><article-title>Soil transmitted helminths and scabies in Zanzibar, Tanzania following mass drug administration for lymphatic filariasis–a rapid assessment methodology to assess impact</article-title><source>Parasit Vectors</source><year>2012</year><volume>5</volume><fpage>299</fpage><pub-id pub-id-type="doi">10.1186/1756-3305-5-299</pub-id><pub-id pub-id-type="pmid">23259465</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Hay</surname><given-names>RJ</given-names></name><name><surname>Steer</surname><given-names>AC</given-names></name><name><surname>Chosidow</surname><given-names>O</given-names></name><name><surname>Currie</surname><given-names>BJ</given-names></name><article-title>Scabies: a suitable case for a global control initiative</article-title><source>Curr Opin Infect Dis</source><year>2013</year><volume>26</volume><issue>2</issue><fpage>107</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1097/QCO.0b013e32835e085b</pub-id><pub-id pub-id-type="pmid">23302759</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Lawrence</surname><given-names>G</given-names></name><name><surname>Leafasia</surname><given-names>J</given-names></name><name><surname>Sheridan</surname><given-names>J</given-names></name><name><surname>Hills</surname><given-names>S</given-names></name><name><surname>Wate</surname><given-names>J</given-names></name><name><surname>Wate</surname><given-names>C</given-names></name><name><surname>Montgomery</surname><given-names>J</given-names></name><name><surname>Pandeya</surname><given-names>N</given-names></name><name><surname>Purdie</surname><given-names>D</given-names></name><article-title>Control of scabies, skin sores and haematuria in children in the Solomon Islands: another role for ivermectin</article-title><source>Bull World Hlth Org</source><year>2005</year><volume>83</volume><issue>1</issue><fpage>34</fpage><lpage>42</lpage></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="book"><collab>World Health Organisation</collab><source>Monitoring and epidemiological assessment of massdrug administration in the global programme to eliminate lymphatic filariasis: a manual for national elimination programmes</source><year>2011</year><publisher-name>Geneva: WHO</publisher-name></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="other"><source>The London Declaration on Neglected Tropical Diseases</source><comment><ext-link ext-link-type="uri" xlink:href="http://www.unitingtocombatntds.org/endorsements">http://www.unitingtocombatntds.org/endorsements</ext-link></comment></mixed-citation></ref></ref-list></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002480 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 002480 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:3639091
|texte= Opportunities to investigate the effects of ivermectin mass drug administration on scabies
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:23594459" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |